文献速递炎症性肠病

整合分子指标与人工智能评估以对接炎症性肠病临床终点

Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease.
PubMed 文献 · Gastroenterology · 2026-02-10

本文讨论将炎症性肠病(IBD)组织与血液样本的多模态分子特征整合到临床实践,以提升临床指标的精细度和治疗反应评估。提出细胞/分子水平的缓解与愈合可能预测长期结局,并强调人工智能辅助工具在实现可重复、低成本、快速检测中的关键作用。

要点

  • 细胞/分子水平的炎症、缓解、愈合与治疗反应指标有望成为IBD未来治疗目标。
  • 监测作用机制特异性药效模块可指导新药与现有疗法的评估。
  • 人工智能辅助工具有助于提高可重复性、降低成本并实现快速检测。

核心结论

  • 将分子疾病描述符作为IBD未来临床治疗目标具有实施路径。

研究设计与样本

  • 综述型文章,基于IBD患者组织与血液样本的多模态分子分析文献进行论述。

主要发现

  • 多模态分析揭示了IBD疾病谱的精细细节及疾病严重程度与结局的细胞和分子关联。

临床怎么用

  • 在临床中整合分子指标可提高现有临床措施的精细度并更好地评估治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multimodal profiling of inflammatory bowel disease (IBD) patient tissue and blood samples has revealed the disease spectrum in unprecedented detail, and cellular and molecular correlates of disease severity and outcome in IBD have been elaborated. Incorporating these in the clinical setting would offer a unique opportunity to increase the granularity of current clinical measures and to better assess treatment response. Remission and healing at a cellular/molecular level are also likely to have predictive value for long-term outcomes. Here, we outline a path forward to implementing the most promising molecular disease descriptors as future clinical treatment targets in IBD. We focus on the concept of cellular/molecular measures of inflammation, remission, healing, response to therapy, and target pathway engagement. Monitoring mode-of-action-specific pharmacodynamic modules in the context of disease-related resolution pathways will guide assessment of novel and existing therapies. Artificial intelligence-assisted tools will be key to enabling this development, improving reproducibility, limiting costs, and delivering fast detection.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Reinisch W, Rittscher J, Iacucci M, et al. Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease. Gastroenterology. 2026. PMID: 41665578. doi:10.1053/j.gastro.2025.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。